Camurus

Declaration of Voting Results & Voting Rights Announcements • Jan 7, 2016

Camurus AB Ideon Science Park SE-223 70 Lund, Sweden www.camurus.com Phone: +46 46 286 57 30

Press release

Change in the number of shares and votes in Camurus

Lund — 30 December 2015 — Camurus AB (publ) (NASDAQ STO:CAMX) today announced that the company's total number of shares as per 30 December 2015 amounts to 37,281,486 shares, corresponding to an equal number of votes. The increase in the number of shares and votes results from the three new share issues of in total 12,072,926 shares which were carried out in connection with the listing of the company's share on Nasdaq Stockholm on 3 December 2015.

About Camurus

Camurus is a Swedish research-based pharmaceutical company committed to developing and commercialising innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the proprietary FluidCrystal® drug delivery technologies and an extensive R&D expertise. Camurus' clinical pipeline includes products for treatment of cancer, endocrine diseases, pain and addiction, developed in-house and in collaboration with international pharmaceutical companies. The company's shares are listed on Nasdaq Stockholm under the ticker "CAMX". For more information, visit www.camurus.com.

For more information

Rein Piir, VP Investor Relations Tel. +46 (0)70 853 72 92 ir@camurus.com

The information in this press release is disclosed by Camurus AB in accordance with the Swedish Securities Markets Act and/or the Swedish Financial Instruments Trading Act. The information was submitted for publication at 07.00 a.m. on 30 December 2015.